PCN236 A Retrospective Real-World Evidence Study of Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS) in the US Using the Optum Database

Abstract

The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has been growing over the last 40 years. 177Lu-DOTATATE (LUT) was approved by the FDA in 2018 for patients with GEP-NETs. We aim to describe the demographic and clinical characteristics of patients with GEP-NETs in the US, and the impact of LUT on healthcare resources using data from the Optum Electronic Health Records (EHR) database. Patients with GEP-NETs were identified from electronic health records using International Classification of Diseases (ICD) versions 9 and 10 diagnosis codes; medications were identified using National Drug Code (NDC) and Healthcare Common Procedure Coding System (HCPCS) codes. Data from January 2018 to March 2020 were included in the analysis. 40,834 patients with GEP-NETs were identified, of which 49.1% were female; 185 of these patients were treated with LUT. Mean (SD) age at diagnosis in overall GEP-NETs patients was 64.8 (14.2) years. 62.7% of patients on LUT had ≥3 co-morbidities (vs 64.9% in overall GEP-NETs). Treatment with LUT led to decreased use of various healthcare services (LUT vs overall GEP-NETS: inpatient visits, 35.1% vs 46.3%; GP visits, 53.5% vs 59.6%; ER visits, 8.6% vs 20.7%). The average length of stay was shorter for patients on LUT (3.9 days vs 7.1 days in overall GEP-NETs). For LUT-treated patients, some visit types increased when compared to the pre-treatment period (35.1% vs 13.0% for inpatient visits; 9.2% vs 1.6% for outpatient visits). Patients with GEP-NETs face a high burden of illness and substantial healthcare service use. In patients receiving LUT in the US, healthcare utilization appears reduced.